Literature DB >> 15832088

KIT and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma.

Huan-You Wang1, Stacey E Mills.   

Abstract

The distinction between chromophobe renal cell carcinoma, the granular cell variant of clear cell renal cell carcinoma, and renal oncocytoma is a common diagnostic dilemma. The usefulness of KIT, CD10, RCC, and RON in the differential diagnosis of these renal epithelial tumors was investigated. KIT was 100% positive in chromophobe renal cell carcinoma (11 of 11) and renal oncocytoma (12 of 12). The KIT staining pattern was identical in both tumor types, with cytoplasmic membrane attenuation, and fine granular cytoplasmic staining. In contrast, KIT was absent in all granular cell variants of clear cell renal cell carcinoma (0 of 6). RCC was observed in more than 80% of the granular cell variant of clear cell renal cell carcinoma (5 of 6) but was negative in all chromophobe renal cell carcinomas (0 of 11) and renal oncocytomas (0 of 12). CD10 was expressed in 100% of the granular cell variant of clear cell renal cell carcinoma (6 of 6), 72% of chromophobe renal cell carcinomas (8 of 11), and 58% of renal oncocytomas (7 of 12). RON was 100% positive in the chromophobe renal cell carcinomas (11 of 11) and renal oncocytomas (12 of 12) but only 50% positive in the granular cell variant of clear cell renal cell carcinoma (3 of 6). Colloidal iron was diffusely and strongly positive in more than 80% of the chromophobe renal cell carcinomas (9 of 11), focally and weakly positive in 41% of the renal oncocytomas (5 of 12) but negative in all granular cell variant of clear cell renal cell carcinoma (0 of 6). The above results demonstrate that: 1) KIT is a very sensitive marker for both chromophobe renal cell carcinoma and renal oncocytoma; 2) immunohistochemistry using antibodies to KIT combined with RCC was sufficient to discriminate between chromophobe renal cell carcinoma and the granular cell variant of clear cell renal cell carcinoma; and 3) neither RON, nor KIT, nor a combination of this panel can be used to distinguish chromophobe renal cell carcinoma from renal oncocytoma. Colloidal iron staining aided in this distinction for the majority of the chromophobe renal cell carcinomas (more than 80% positive) and renal oncocytomas (close to 60% negative).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15832088     DOI: 10.1097/01.pas.0000157943.33903.92

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  13 in total

1.  Renal tumors: diagnostic and prognostic biomarkers.

Authors:  Puay Hoon Tan; Liang Cheng; Nathalie Rioux-Leclercq; Maria J Merino; George Netto; Victor E Reuter; Steven S Shen; David J Grignon; Rodolfo Montironi; Lars Egevad; John R Srigley; Brett Delahunt; Holger Moch
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

2.  Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.

Authors:  Pedram Argani; Jessica Hicks; Angelo M De Marzo; Roula Albadine; Peter B Illei; Marc Ladanyi; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2010-09       Impact factor: 6.394

3.  Histology is a Prognostic Indicator After Pulmonary Metastasectomy from Renal Cell Carcinoma.

Authors:  Yoichi Ohtaki; Kimihiro Shimizu; Keiju Aokage; Masayuki Nakao; Junji Yoshida; Mitsuhiro Kamiyoshihara; Masayuki Sugano; Yusuke Takahashi; Seshiru Nakazawa; Toshiteru Nagashima; Kai Obayashi; Tomoyuki Hishida; Masahiro Tsuboi; Shohei Mori; Mingyon Mun; Sakae Okumura; Hitoshi Igai; Noriyuki Matsutani; Akira Mogi; Hiroyuki Kuwano
Journal:  World J Surg       Date:  2017-03       Impact factor: 3.352

4.  t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases.

Authors:  Nathaniel E Smith; Peter B Illei; Mohamed Allaf; Nilda Gonzalez; Kerry Morris; Jessica Hicks; Angelo Demarzo; Victor E Reuter; Mahul B Amin; Jonathan I Epstein; George J Netto; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

5.  Prognostic significance of MST1R dysregulation in renal cell tumors.

Authors:  Ana S Pires-Luís; Márcia Vieira-Coimbra; Maria João Ferreira; João Ramalho-Carvalho; Pedro Costa-Pinheiro; Luís Antunes; Paula C Dias; Francisco Lobo; Jorge Oliveira; Inês Graça; Rui Henrique; Carmen Jerónimo
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

6.  Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade.

Authors:  Elizabeth M Genega; Musie Ghebremichael; Robert Najarian; Yineng Fu; Yihong Wang; Pedram Argani; Chiara Grisanzio; Sabina Signoretti
Journal:  Am J Clin Pathol       Date:  2010-12       Impact factor: 2.493

Review 7.  Morphological approach to tumours of the testis and paratestis.

Authors:  Robert E Emerson; Thomas M Ulbright
Journal:  J Clin Pathol       Date:  2007-02-16       Impact factor: 3.411

8.  Immunohistochemical marker panel differentiates between the three most common subtypes of renal cell carcinoma independent from histomorphologic criteria.

Authors:  B Walter; A Hartmann; F Hofstädter; K Junker; H Moch; S Bertz; S Denzinger; W Otto; M Gajda; C G Stoehr
Journal:  Virchows Arch       Date:  2012-02-17       Impact factor: 4.064

Review 9.  Key clinical issues in renal cancer: a challenge for proteomics.

Authors:  Rosamonde E Banks; Rachel A Craven; Patricia Harnden; Sanjeev Madaan; Adrian Joyce; Peter J Selby
Journal:  World J Urol       Date:  2007-08-25       Impact factor: 4.226

10.  Histological reclassification, histochemical characterization and c-kit immunoexpression in renal cell carcinoma.

Authors:  P R Rekha; S Rajendiran; Shalinee Rao; Sunil Shroff; Leena D Joseph; D Prathiba
Journal:  Indian J Urol       Date:  2008-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.